🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "major milestone" in the battle against increasingly resistant strains of the infection, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are increasing worldwide, with figures suggesting in excess of 82 million infections annually. Particularly high rates are reported in Africa and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary development in the context of growing infection rates, increasing antimicrobial resistance and the extremely scarce available drugs currently available.”

Health officials are deeply concerned about the increase in antibiotic-resistant strains. The WHO has classified it as a "critical concern". Recent surveillance found that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Secure Approval

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US FDA in mid-December for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Experts hope that specific application of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GSK, was also approved in close succession. This drug, which is employed against UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a unique collaborative effort for medication research. The charitable organization GARDP collaborated with the drug firm Innoviva to bring it to fruition.

“This milestone marks a huge turning point in the treatment of superbug gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Clinical Trial Data and Global Access

According to results released by a major medical journal, zoliflodacin successfully treated the vast majority of cases of the STI. This establishes an equal footing with the current standard treatment, which involves a dual-drug approach. The study involved over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the ability to make available and distribute the drug in a wide range of low-income and middle-income countries.

Doctors on the front lines have voiced positive views. Having a one-pill regimen like this is described as a "revolutionary step" for public health efforts. This is considered vital to lessen the impact of the disease for individuals and to halt the transmission of extremely resistant gonorrhoea around the world.